Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
Search
Partnering Purpose: BI Gives Back | Boehringer Ingelheim US
Hear from Sheila Denton, Senior Vice President, General Counsel and Corporate Secretary, on the importance of giving back to our communities.
Partnering Days
Partnering Days
Meet the Animal Health Partnering Team
Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.
Improving Access to Clinical Trials
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Boehringer Ingelheim Launches External Innovation Hub in China
Boehringer Ingelheim Launches External Innovation Hub in China
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
About Boehringer Ingelheim Academy
About Boehringer Ingelheim Academy
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Our Partnering Approach in Animal Health
Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics For Geographic Atrophy, a Leading Cause of Blindness Worldwide
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics For Geographic Atrophy, a Leading Cause of Blindness Worldwide
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Partnering in CardioMetabolic Diseases
Partnering in CardioMetabolic Diseases
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Life forward - Boehringer Ingelheim unveils its evolved company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health
Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim Acquires AMAL Therapeutics
Boehringer Ingelheim Acquires AMAL Therapeutics
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
Submit Your Partnering Opportunity
Submit Your Partnering Opportunity
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.